| Name | Title | Contact Details |
|---|---|---|
Caitlin McWilliams |
VP of Finance and Corporate | Profile |
Leo Grady |
Chief Executive Officer | Profile |
Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.
Biosome is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Targeted Genetics Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Xenotech is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionova Holding Corporation acts as a holding company for Agrobionova, S.A. de C.V. (ABSA), of which it owns 98.6%, International Produce Holding Company (IPHC), which is wholly owned, DNA Plant Technology Corporation (DNAP), a wholly owned entity, and